Akums Drugs & Pharmaceuticals has launched a novel combination therapy of ripasudil and timolol for managing glaucoma and ocular hypertension. Approved by the DCGI, this marks the first Indian CDMO to bring such a formulation to market—offering a dual-action approach for improved eye pressure control.

Key Highlights

First-of-its-kind dual therapy in India

• Akums becomes the first Indian contract development and manufacturing organisation (CDMO) to launch the ripasudil+timolol combination.

• Approved by the Drugs Controller General of India (DCGI).

Stronger IOP control for glaucoma and ocular hypertension

• Ripasudil improves fluid outflow through the trabecular meshwork.

• Timolol reduces fluid production in the eye.

• The dual mechanism provides more effective and sustained intraocular pressure (IOP) reduction.

Simplified treatment, better patient adherence

• The single-drop combo simplifies glaucoma treatment regimens.

• Improved ease of use is expected to enhance compliance, a key challenge in long-term glaucoma management.

Make-in-India push for ophthalmic innovation

• Akums plans to use its advanced facilities to ensure consistent availability.

• The initiative aligns with India’s goal of promoting self-reliant pharmaceutical innovation.

Statements from Leaders or Officials
 Sanjeev Jain, MD, Akums: “This innovation integrates two mechanisms to deliver better glaucoma outcomes. It’s part of our patient-first, Make-in-India approach to develop globally aligned, high-quality products.”
 Sandeep Jain, MD, Akums: “With rising glaucoma prevalence, improving efficacy and access is critical. This therapy offers both.”With nearly 11.9 million Indians affected by glaucoma, Akums’ ripasudil+timolol combination addresses a significant unmet need. By enhancing both efficacy and patient adherence, this launch could reshape the future of ophthalmic care in India.